We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Adocia | EU:ADOC | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.44 | -7.05% | 5.80 | 5.80 | 5.89 | 6.65 | 5.52 | 6.22 | 370,816 | 16:40:00 |
Saturday 21 December 2024
Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced its financial calendar for 2025.
February 25, 2025
Publication of revenue for Q4 2024
April 17, 2025
Publication of 2024 financial statements
May 14, 2025
Publication of revenue for Q1 2025
June 11, 2025
Annual shareholders’ meeting
July 23, 2025
Publication of revenue for Q2 2025
September 25, 2025
Publication of mid-year financial statements as of June 30, 2025
October 15, 2025
Publication of revenue for Q3 2025
In addition to regular meetings with the financial community, investors can also find updated information on the company’s website (www.adocia.com).
All corporate information on the company such as its financial statements, its corporate presentation and its status is available on the company’s website, in the Investors’ section “Regulated Information”.
About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.
The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform.
Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
View source version on businesswire.com: https://www.businesswire.com/news/home/20241219542517/en/
Adocia
Olivier Soula CEO
contactinvestisseurs@adocia.com +33 (0)4 72 610 610 www.adocia.com
Ulysse Communication
Adocia Press & Investor Relations Bruno Arabian Nicolas Entz
adocia@ulysse-communication.com + 33 (0)6 87 88 47 26
1 Year Adocia Chart |
1 Month Adocia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
